Published in BMC Neurol on October 13, 2009
Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain. Front Syst Neurosci (2014) 0.94
The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev (2011) 0.91
Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open (2013) 0.78
EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome. BMC Psychiatry (2013) 0.76
Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study. BMC Psychiatry (2016) 0.75
Public Health Literature Review of Fragile X Syndrome. Pediatrics (2017) 0.75
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med (2001) 11.48
FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med (2001) 3.84
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
The fragile X prevalence paradox. J Med Genet (2008) 3.05
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 2.76
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg (2000) 2.40
Autism profiles of males with fragile X syndrome. Am J Ment Retard (2008) 2.35
Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord (2007) 2.28
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet (2008) 2.20
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr (2008) 1.91
Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess (2003) 1.69
Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav (2005) 1.65
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol (2006) 1.47
The fragile X continuum: new advances and perspectives. J Intellect Disabil Res (2008) 1.39
Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev (2004) 1.36
A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet (1988) 1.23
The fragile X syndrome. A study of 83 families. Clin Genet (1984) 1.10
Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology (2008) 1.09
Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am (2007) 1.06
Open-label memantine in fragile X syndrome. J Autism Dev Disord (2009) 1.04
Using percentile schedules to increase eye contact in children with Fragile X syndrome. J Appl Behav Anal (2009) 1.02
A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A (2008) 0.96
Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A (2009) 0.96
Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord (2008) 0.95
Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol (2005) 0.94
The acquisition of stimulus equivalence in individuals with fragile X syndrome. J Intellect Disabil Res (2006) 0.93
Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res (2008) 0.87
Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet (1986) 0.87
Folic acid treatment in males and females with fragile-(X)-syndrome. Am J Med Genet (1986) 0.84
Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008). Behav Neurosci (2008) 0.84
Folic acid therapy in the fragile X syndrome. Am J Med Genet (1984) 0.84
Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet (1999) 0.82
Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome. Am J Med Genet (1992) 0.81
Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol (1986) 0.79
Measurement of problem behaviour during medication evaluations. J Intellect Disabil Res (2008) 0.79
Folic acid treatment of fragile X males: a further study. Am J Med Genet (1988) 0.79
Folic acid blinded trial in identical twins with fragile X syndrome. Am J Hum Genet (1985) 0.79
High dose folic acid treatment of fragile (X) males. Am J Med Genet (1986) 0.79
Brief review of current research in FXS: implications for treatment with psychotropic medication. Res Dev Disabil (2006) 0.77
Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: a double-blind, placebo-controlled study. J Clin Psychopharmacol (1991) 0.77
A controlled study of folic acid treatment in three fragile X syndrome males. J Dev Behav Pediatr (1986) 0.76
MS/MS networking guided analysis of molecule and gene cluster families. Proc Natl Acad Sci U S A (2013) 2.12
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry (2010) 1.55
CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat (2006) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis. Eur Arch Psychiatry Clin Neurosci (2010) 1.05
Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 1.05
Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA (2007) 1.04
Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci. Am J Hum Genet (2009) 0.99
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer (2013) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics (2013) 0.91
Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Health Qual Life Outcomes (2013) 0.88
Microbiota of healthy corals are active against fungi in a light-dependent manner. ACS Chem Biol (2014) 0.85
Risk of cognitive impairment in female premutation carriers of fragile X premutation: analysis by means of robust segmented linear regression models. Am J Med Genet B Neuropsychiatr Genet (2009) 0.85
[A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale]. Med Clin (Barc) (2003) 0.85
[Validation of the Spanish version of the Subjective Well-being under Neuroleptic Scale (SWN-K) in patients with schizophrenia]. Med Clin (Barc) (2011) 0.82
Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence (2011) 0.82
Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful. Histopathology (2012) 0.81
Dimensions of mania: differences between mixed and pure episodes. Eur Psychiatry (2004) 0.81
Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes. Ann Gen Psychiatry (2012) 0.80
Trisomy 18p caused by a supernumerary marker with a chromosome 13/21 centromere: a possible recurrent chromosome aberration. Am J Med Genet A (2013) 0.80
[A validation study of the Spanish versions of the Clinical Anxiety Scale and the Physician Questionnaire for the assessment of anxiety disorders]. Med Clin (Barc) (2003) 0.79
Outcome of memory rehabilitation in traumatic brain injury assessed by neuropsychological tests and questionnaires. J Head Trauma Rehabil (2004) 0.78
Effectiveness of a psychoeducational intervention group program in the reduction of the burden experienced by caregivers of patients with dementia: the EDUCA-II randomized trial. Alzheimer Dis Assoc Disord (2014) 0.78
Sexual functioning in women and men with fibromyalgia. J Sex Med (2011) 0.77
The subjective well-being under neuroleptic scale - short version (SWN-K) and the SF-36 health survey as quality of life measures in patients with schizophrenia. Patient Prefer Adherence (2012) 0.77
Folic acid for fragile X syndrome. Cochrane Database Syst Rev (2011) 0.76
Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction (2014) 0.76
MTHFR 677TT genotype and toxicity of methotrexate: controversial results. Cancer Chemother Pharmacol (2011) 0.75
Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data. BMC Cancer (2014) 0.75
[Attention deficits and response to drug therapy in patients with treatment-resistant schizophrenia: results through confirmatory factor analysis]. Rev Psiquiatr Salud Ment (2010) 0.75
[Impact of collective violence on health status. Results of the ISAVIC study in the Basque Region (Spain)]. Gac Sanit (2011) 0.75
An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol (2007) 0.75
Suicidal ideation in patients with fibromyalgia: a cross-sectional study. Pain Pract (2014) 0.75
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour. Anticancer Drugs (2012) 0.75
[How does collective violence shape the health status of its victims? Conceptual model and design of the ISAVIC study]. Gac Sanit (2011) 0.75
Chromosome instability in lymphocytes of children with coeliac disease. J Pediatr Gastroenterol Nutr (2009) 0.75
L-acetylcarnitine for treating fragile X syndrome. Cochrane Database Syst Rev (2015) 0.75
[HIV infection and injecting drug users: The urgency of reinvigorating harm-reduction programmes]. Adicciones (2010) 0.75